Lincoln Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 ,inter alia, to consider and approve Standalone and Consolidated ....
LINCOLN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lincoln Pharmaceuticals has informed the stock exchanges that its Board of Directors will meet on Thursday, 13th November 2025. The main agenda is to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended 30th September 2025 (Q2 FY26 / H1 FY26). Any other business may be taken up with the Chairman's permission. The trading window for dealing in company securities has been closed since 1st October 2025 and will reopen 48 hours after the results are publicly available. This is a routine regulatory intimation under SEBI Listing Regulations, with no actual financial figures disclosed at this stage.
No direct impact on shareholders or stock price from this announcement itself — it is a standard advance notice. Investors should watch for the actual Q2/H1 FY26 results on 13th November, which could move the stock depending on performance versus expectations. The trading window closure also means insiders cannot trade until after results are announced.